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Abstract
Background: Schitosomiasis japonica is still a significant public health problem in China. A protective vaccine for human
or animal use represents an important strategy for long-term control of this disease. Due to the complex life cycle of
schistosomes, different vaccine design approaches may be necessary, including polyvalent subunit vaccines. In this study,
we constructed four chimeric proteins (designated SjGP-1~4) via fusion of Sj26GST and four individual paramyosin
fragments. We tested these four proteins as vaccine candidates, and investigated the effect of deviating immune response
on protection roles in mice.
Methods: The immunogencity and protection efficacy of chimeric proteins were evaluated in mice. Next, the chimeric
protein SjGP-3 was selected and formulated in various adjuvants, including CFA, ISA 206, IMS 1312 and ISA 70M. The
titers of antigen-specific IgG, IgE and IgG subclass were measured. The effect of adjuvant on cytokine production and
percentages of CD3+CD8-IFN-γ+ cells and CD3+CD8-IL-4+ cells were analyzed at different time points. Worm burdens
and liver egg counts in different adjuvant groups were counted to evaluate the protection efficacy against cercarial
challenge.
Results: Immunization of mice with chimeric proteins provided various levels of protection. Among the four proteins,
SjGP-3 induced the highest level of protection, and showed enhanced protective efficacy compared with its individual
component Sj26GST. Because of this, SjGP-3 was further formulated in various adjuvants to investigate the effect of
adjuvant on immune deviation. The results revealed that SjGP-3 formulated in veterinary adjuvant ISA 70M induced a
lasting polarized Th1 immune response, whereas the other adjuvants, including CFA, ISA 206 and IMS 1312, generated a
moderate mixed Th1/Th2 response after immunization but all except for IMS 1312 shifted to Th2 response after onset
of eggs. More importantly, the SjGP-3/70M formulation induced a significant reduction in liver egg deposition at 47.0–
50.3% and the number of liver eggs per female at 34.5–37.2% but less effect on worm burdens at only 17.3–23.1%,
whereas no effect of the formulations with other adjuvants on the number of liver eggs per female was observed.
Conclusion: Construction of polyvalent subunit vaccine was capable to enhance immunogenicity and protection efficacy
against schistosomiasis. There was correlation of the polarized Th1 response with reduction of liver egg burdens,
supporting the immune deviation strategy for schistosomiasis japonica vaccine development.
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Background
Schistosomiasis remains one of the most prevalent para-
sitic diseases in the world, affecting more than 200 mil-
lion people in developing countries [1]. Of the three
major schistosome species that infect humans, Schistosoma
japonicum is recognized as the most difficult to control
because of its zoonotic nature. Several types of important
livestock, such as water buffaloes and domestic pigs, are
main reservoir hosts of S. japonicum, and eggs in their feces
are of prime importance for continued transmission of
this parasite in humans. In the past five decades, schisto-
somiasis has been largely controlled in China through
widespread treatment with the anti-schistosome agent,
praziquantel, plus large-scale environmental campaigns
to eradicate the intermediate host snail. However, there
has been a resurgence of schistosomiasis in recent years in
some provinces of China, due to the inability of chemo-
therapy to prevent new infection and difficulties associ-
ated with snail intermediate hosts eradication [2]. As a
result, a protective vaccine for human or domestic animal
use represents an important strategy for long-term control
of schistosomiasis japonica [3,4].
Numerous antigens have been identified as schistosomia-
sis japonica vaccine candidates [5]. Among them, S. japon-
icum  26 kDa glutathione S-transferase (Sj26GST) and
paramyosin are two leading vaccine candidates. In the
schistosome, GSTs are expressed in the parenchymal cells
of male parasites and in the parenchymal cells between
the vitelline glands in female worms [6,7]. They function
to detoxify and remove harmful molecules from the
organisms [8]. Vaccination of mice with Sj26GST pro-
vided a moderate level of protection [9]. Paramyosin is a
97 kDa myofibrillar protein with a coiled-coil structure
that is widely distributed in S. japonicum at different life
stages, including cercariae, lung-stage schistosomula, and
in adult worms [6]. Immunization of animals with native
and recombinant paramyosin conferred significant pro-
tection against challenge with S. japonicum [10,11]. In our
previous study, we divided paramyosin into four overlap-
ping fragments (Pmy-F1, Pmy-F2, Pmy-F3, and Pmy-F4)
to evaluate the protective efficacy of each fragment. We
found all four fragments of paramyosin produced similar
levels of protection in mice [12].
Although both Sj26GST and paramyosin provide a certain
level of protection against schistosome infection, neither
has consistently provided sufficient levels of protection
[4]. Due to the complex life cycle of schistosome, uncon-
ventional vaccine design approaches may be needed.
Recently, a novel approach utilizing a polyvalent subunit
vaccine has been successfully applied by our group to the
PfCP-2.9 chimeric vaccine candidate against malaria,
another parasite with a complex life cycle [13-15]. Such
chimeric proteins are capable of enhancing immuno-
genicity and inhibiting parasite growth. Based on our suc-
cessful experience with the polyvalent subunit malaria
vaccine, we have now constructed four S. japonicum chi-
meric proteins, designated SjGP-1, SjGP-2, SjGP-3 and
SjGP-4, comprised of the full-length Sj26GST sequence
and Pmy-F1, Pmy-F2, Pmy-F3 or Pmy-F4, respectively.
These chimeric proteins were tested in mice for immuno-
genicity and protective efficacy against challenge with S.
japonicum in the current study.
Many studies highlight the importance of immunoregula-
tory role of cytokines associated with Th1/Th2 immune
responses in both anti-parasite and anti-pathology immu-
nity. Therefore, immune deviation has been considered a
modern immunology strategy for schistosomiasis vaccine
development [16]. Many factors were shown to influence
immune response, but use of adjuvant would be a useful
protocol for immune deviation [17]. In an attempt to
increase the efficacy of chimeric protein constructed in
this study and to investigate the effect of deviating
immune response on protection roles, SjGP-3, the chi-
meric protein that gave the best protective efficacy in chal-
lenge experiment, was formulated with four different
adjuvants (CFA, Montanide® ISA 206, Montanide® IMS
1312 and Montanide® ISA 70M) and tested in mice. SjGP-
3 emulsified with the veterinary adjuvant ISA 70M
induced a strong polarized Th1 immune response after
immunization and this SjGP-3-driven Th1 response could
be maintained after cercarial challenge. However, the
same antigen formulated with CFA or ISA 206 induced a
moderate mixed Th1/Th2 immune response after vaccina-
tion, but this mixed immune response shifted to Th2
immune response after parasite maturation and onset of
egg production. Importantly, the SjGP-3-inducing polar-
ized Th1 immune response was significantly associated
with the reduction of liver egg burdens as well as the
number of liver eggs per female worm.
Methods
Parasites and animals
A mainland strain of Schistosoma japonicum used for all
experiments was originally maintained in Oncomelania
hupensis snails and in New Zealand White rabbits. Six to 8-
week-old BALB/c mice were purchased from the Songjiang
Animal Facility of the Chinese Academy of Sciences of
Shanghai. Seven weeks after cercarial challenge, adult
worms were recovered by perfusion of infected rabbits
and homogenized in cold buffer containing 140 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2
mM phenyl methyl sulfonyl fluoride (PMSF). Soluble
worm antigen products (SWAP) were obtained from adult
worms following sonication and centrifugation [18]. To
purify the native Sj26GST of adult worm, SWAP was
applied to the Glutathione Sepharose 4B column (Amer-
sham Bioscience, USA). The column was then washedBMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
Page 3 of 14
(page number not for citation purposes)
with PBS and the bound material was eluted with elution
buffer containing 10 mM Glutathione in 50 mM Tris-HCl,
pH8.0.
Construction of chimeric proteins
The amino acid sequence of paramyosin of S. japonicum
mainland strain (Genbank accession number:
AAD29285) was translated into a DNA sequence using
yeast (Pichia pastoris) codon usage [19]. The resulting DNA
sequence was divided into four fragments that were syn-
thesized separately as described in our previous study
[20]. The individual synthesized fragment was inserted
into the vector pGEX-4T-1 via BamHI and EcoRI restriction
sites in frame with the coding sequence of Sj26GST which
was located on the vector so that individual chimeric pro-
tein consisting of Sj26GST and individual paramyosin
fragment. The sequence of each chimeric protein was then
generated by PCR using the upstream primer, P0: 5'-GC
CTC GAG AAA AGA ATG TCC CCT ATA CTA GGT-3', and
four different downstream primers, P1: 5'-CC GAA TTC
CTA TTA GTG ATG ATG GTG GTG ATG GAA ACG ATT
TCT AGA TTC ATC-3'; P2: 5'-CC GAA TTC CTA TTA GTG
ATG ATG GTG GTG ATG GGA ACG CAA AGC TTC CAG
GTC-3'; P3: 5'-CC GAA TTC CTA TTA GTG ATG ATG GTG
GTG ATG GGC TTG CAT GAC GCC AAT GTC-3'; P4: 5'-
CC GAA TTC CTA TTA GTG ATG ATG GTG GTG ATG CAT
CAT AGA TGT AGC TCT CAT AC-3'. The resulting PCR
products were first inserted into the vector pPIC9, respec-
tively, and then each SacI/SalI fragment was excised from
the recombinant pPIC9 plasmids and inserted into the
Pichia  expression vector, pPIC9K. To facilitate purifica-
tion, 6 × His tags were included at the C-terminus of the
chimeric proteins.
Expression of the chimeric genes in either Pichia pastoris 
or E. coli
The recombinant pPIC9K plasmids were linearized before
transfered by electroporation into Pichia pastoris GS115.
Selection of His+ transformants and G418-resistant clones
was carried out according to the manufacturer's instruc-
tion manual (Invitrogen, USA). The selected clones were
first cultured in 3 ml Minimal Glycerol Medium at 30°C
overnight until the OD (600 nm) reached to 2–6. Cells
were then grown in 3 ml Buffered Methanol-complex
Medium containing 0.5% (v/v) methanol for induction of
protein expression. Methanol was added to the culture at
24 h intervals to maintain the final concentration at 0.5%
(v/v). To express the protein in a 15-L fermentor, a 250 mL
culture of yeast cells was first grown at 30°C for 22 h in
Minimal Glycerol Medium and then inoculated into the
fermentor containing 6000 mL of minimal salts fermenta-
tion medium. The cells were grown at 30°C and harvested
at 48 h after methanol induction.
For those fusion proteins that failed to be expressed in
Pichia, the recombinant plasmids based on pGEX-4T-1
were transformed into E. coli BL21 (DE3) strain. The
selected clones were grown first in LB/Amp+ at 37°C for 3
h. Then IPTG was added at 0.5 mM to induce protein
expression at 25°C for 5 h in shake flasks.
Purification of recombinant proteins
To purify the recombinant proteins produced in P. pas-
toris, the fermentation supernatant was dialyzed exten-
sively against dialyzing buffer containing 20 mM sodium
phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4. To
purify the recombinant proteins produced in E. coli, cells
were harvested and disrupted by sonication in the dialyz-
ing buffer described above. The dialyzed fermentation
supernatant or E. coli cell lysate supernatant material was
applied to a Ni-NTA column (Qiagen, Germany) for puri-
fication. Further purification was carried out on a Glutath-
ione Sepharose 4B column (Amersham Bioscience). LPS
contamination in purified proteins was excluded by Limu-
lus lysate test (SIGMA, USA). Protein concentration was
determined by the Bradford method [21].
Immunization schedule
Mice were injected s. c. with 20 μg of recombinant fusion
proteins or Sj26GST in 50 μl PBS formulated with an
equal volume of complete Freund's adjuvant (CFA,
SIGMA) or incomplete Freund's adjuvant (IFA, SIGMA) at
3-week intervals. CFA was used for the initial immuniza-
tion and IFA for the two subsequent boosts. The control
group was subjected to the same immunization schedule,
but PBS replaced the fusion proteins.
In the experiment to evaluate the protective efficacy of one
fusion protein mixed with different adjuvants, the recom-
binant fusion protein that produced the best protective
efficacy, SjGP-3, was selected as the antigen. Four different
adjuvants were tested separately: CFA, ISA206, IMS1312
and ISA 70M. Mice were injected s. c. with 20 μg SjGP-3
protein in PBS formulated with CFA, ISA206, IMS1312 or
ISA 70M, respectively. The formulations of ISA 206, IMS
1312 and ISA 70M were issued by SEPPIC (France).
Briefly, the antigen was added in ISA 206, IMS 1312 and
ISA 70M at a ratio of 46:54, 50:50 and 30:70 (m/m),
respectively. The formulations were stirred for 15 to 30
min at 2000 rpm. Except for CFA, the adjuvants were also
used for the two subsequent boosts at 3-week intervals.
The control group was injected with PBS instead of fusion
protein and adjuvants. The experiment was repeated
twice.
Immunoblotting
The purified native Sj26GST or SWAP was separated by
SDS-PAGE and then transferred onto a 0.45 μm of PVDF
membrane using a Bio-Rad protein transfer unit. Mem-BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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branes were probed with sera from immunized mice,
incubated with goat-anti-mouse IgG-AP, and revealed by
NBT-BCIP detection system (SIGMA).
Measurement of antigen-specific antibody
Serum samples were collected before injection and on
week 2, 5 and 8 after the initial immunization. Enzyme-
linked immunosorbent assay (ELISA) was performed to
detect the levels of different isotypes against the fusion or
individual proteins using HRP-labeled goat antibodies
specific for IgG, IgE and IgG subclasses (Bio-Rad, USA).
ELISA was performed as described before [12]. Cut-off val-
ues were determined from the mean plus three standard
deviations from the pre-immunization sera.
Quantification of IL-4 and IFN-γ
On week 9 (before challenge), 12(three weeks after cercar-
ial challenge) and 15 (six weeks after cercarial challenge),
spleen cells from individual mice were cultured at 5 × 106
cells/well in 24-well plates (Corning, USA) in RPMI 1640
medium (Gibico, USA) supplemented with 10% fetal calf
serum (SIGMA). Anti-CD3 (1 μg/ml), recombinant pro-
tein (30 μg/ml) or medium was used to stimulate spleno-
cytes. At 72 h after stimulation, supernatants were
collected for cytokine analysis. The production of IL-4 and
IFN-γ were measured by ELISA as described [22,23] by
cytokine-specific Abs, recombinant cytokine standards,
biotinylated detection Abs, and avidin-HRP (eBioscience,
USA).
Intracellular cytokine detection by flowcytometry
Splenocytes (2 × 106 cells/ml) were harvested from mice
immunized with SjGP-3 formulated with various adju-
vants on week 9, 12 and 15, and stimulated with 25 ng/ml
phorbol myristate acetate (PMA), 1 ug/ml ionomycin plus
1 ug/ml brefeldin A (BFA) (SIGMA) at 37°C for 6 h on a
24-well plate (Corning). Splenocytes were stained extra-
cellularly with PE-Cy5 conjugated anti-CD3 and FITC
conjugated anti-CD8 (eBioscience). After fixation in
FIX&Perm Medium A (CALTAG, USA), cells were stained
intracellularly with PE conjugated Rat IgG1 (isotype con-
trol), anti-mouse IFN-γ antibody or anti-mouse IL-4 anti-
body (eBioscience) in FIX&Perm Medium B (CALTAG). A
FACScan flow cytometer with Cell Quest software was
used for data acquisition and analysis.
Cercarial challenge and determination of resistance
On week 9, mice were challenged with cercariae. Mice
were fixed in wooden plates and the hairs on the abdo-
men were shaved by an animal clipper. The shaved part
was then wetted with dechlorine tap water. Each mouse
was infected with 40 ± 2 cercariae, which were placed on
a coverglass (12 × 12 mm) with the aid of a capillary drop-
per under microscope. The coverglass was then placed up
side down on the shaved area for at least 20 minutes.
On week 15, adult worms were recovered by perfusion
from the mesenteric vein. Livers were weighed and proc-
essed as described previously [12]. Briefly, the livers were
digested with 4% KOH overnight, and the number of eggs
was determined by microscopic examination. Total adult
worm burdens and liver eggs were counted. The level of
protection of vaccinated group was calculated as a per-
centage based on the reduction in worm burdens or liver
eggs per gram of liver, compared with those from the con-
trol group. The reduction rate of liver eggs per female
worm was also calculated according to the following for-
mula: (1-mean number of liver eggs per female worm in
immunized mice/mean number of liver eggs per female
worm in control mice) ×100.
Statistical analysis
Data of worm burdens and egg counts were expressed as
the mean ± standard error. The other data were expressed
as the mean ± standard deviation. Multiple comparisons
were analyzed by a LSD one-way ANOVA test, with a p-
value < 0.05 considered significant. We used SPSS version
13 for all statistical analyses.
Results
Construction and expression of chimeric genes
Four overlapping fragments derived from S. japonicum
paramyosin were generated in our previous study using
codon optimization and gene synthesis. The chimeric pro-
teins were constructed by fusing paramyosin fragments
with Sj26GST gene, via a hinge of six amino acid residues
that was the thrombin recognition site (Figure 1A). The
resulting fusion fragments were then inserted into the vec-
tor pPIC9K for expression in Pichia. After methanol induc-
tion, only the SjGP-2 protein was detected in supernatant
of the yeast culture; no other constructs were detected in
this system. Alternatively, the remaining three genes
(SjGP-1, SjGP-3 and SjGP-4) were successfully produced
in soluble form after induction by 0.5 mM IPTG at 25°C
in E. coli.
To facilitate purification of protein, a 6 × His tag was
incorporated at the C-terminus of each construct, allow-
ing isolation of recombinant protein on a Ni-NTA col-
umn. Because each construct contained Sj26GST, it was
also possible to isolate the chimeric proteins by Glutath-
ione Sepharose 4B column. Thus, all of the recombinant
proteins were purified by combining the purification
processes of Ni-NTA with Glutathione Sepharose 4B affin-
ity chromatography. The purities of proteins were close to
95% as determined by SDS-PAGE, with the exception of
SjGP-4, in which a degradation product was observed
(Figure 1B) and confirmed by Western blotting using
mouse immune sera against Sj26GST or Pym-F4, retained
in our lab (data not shown).BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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Immunogencity of the chimeric proteins
The amount of IgG in serum collected on week 8 was
determined by ELISA. Antibody titers were measured
against purified fusion proteins (SjGP-1 to SjGP-4) and
individual components (Sj26GST and the corresponding
paramyosin fragments Pmy-1 to Pmy-4). High levels of
antigen-specific antibodies were elicited by all fusion pro-
teins after three times immunization. Of these, SjGP-1
and SjGP-3 induced the highest levels of antibodies at tit-
ers of 1/1,310,000 and 1/1,231,000, respectively. Moreo-
ver, the antibodies to chimeric proteins recognized both
of the individual components, Sj26GST and the corre-
sponding paramyosin fragments (Table 1). To investigate
whether the antibodies induced by the recombinant chi-
meric proteins can recognize native paramyosin and
Sj26GST, soluble worm antigen products (SWAP) were
Schematic representation of chimeric gene constructs, recombinant proteins and interaction of immune sera with native pro- teins Figure 1
Schematic representation of chimeric gene constructs, recombinant proteins and interaction of immune sera 
with native proteins. (A) Schematic representation of SjGP-1, SjGP-2, SjGP-3, and SjGP-4 gene construction. Paramyosin 
was divided into four overlapping fragments and the length of amino acid (Aa) sequence of each fragment is indicated. Each par-
amyosin fragment was fused to Sj26GST to generate chimeric gene via a hinge (H) consisting of six amino acid residues that 
were the thrombin recognition site. (B) Purity analysis of purified chimeric proteins by SDS-PAGE. Lane M: molecular mass 
maker; lanes 1 to 4: purified SjGP-1, SjGP-2, SjGP-3, and SjGP-4 protein, respectively. (C) Interaction of immune sera against 
the individual chimeric proteins with soluble worm antigen preparation (SWAP) by Western Blot. The SWAP material was 
separated by SDS-PAGE and analyzed by Western Blot using either immune sera to the individual chimeric proteins or nega-
tive control sera. Lane M: molecular mass maker; lanes 1 to 4: sera of mice immunized with SjGP-1, SjGP-2, SjGP-3, and SjGP-
4, respectively; lane 5: serum from PBS control mice. (D) Interaction of immune sera against the individual chimeric proteins 
with purified native Sj26GST. The purified native Sj26GST was separated by SDS-PAGE and analyzed by Western Blot using 
either immune sera to individual chimeric protein or negative control sera. Lane M: molecular mass maker; lanes 1 to 4: sera of 
mice immunized with SjGP-1, SjGP-2, SjGP-3, and SjGP-4, respectively; lane 5: serum from PBS control mice.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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probed by Western blotting using mouse anti-sera
obtained after the third vaccination. As shown in Figure
1C, antibodies to chimeric proteins bound to bands at 97
kDa (Figure 1C, lanes 1–4), whereas no specific protein
band was detected using pre-immune sera (Figure 1C,
lane 5). However, the 26 kDa Sj26GST protein was not
detected in this preparation, perhaps due to low level
expression of this protein in vivo. Therefore, the native
Sj26GST was first concentrated from SWAP by a purifica-
tion process using Glutathione Sepharose 4B column.
Then the purified product was tested. The protein bands at
26 kDa were consistently detected by immune sera (Figure
1D, lanes 1–4).
Protection efficacy against cercarial challenge
Mice were infected percutaneously with 40 cercariae of S.
japonicum by the cover method (as described in Method).
Mice were sacrificed on week 15 (six weeks after a chal-
lenge infection). Adult worms were recovered by per-
fusion from the mesenteric vein and liver eggs were
counted. As shown in Table 1, compared with control
group, worm burdens of vaccinated mice were reduced (P
< 0.05) by 27.7%, 37.5% and 20.7% for SjGP-1, SjGP-3 or
SjGP-4, respectively. SjGP-2 vaccination did not reduce
worm burdens (4.2%, P > 0.05). More importantly, fusion
protein SjGP-3 enhanced protection against worm bur-
dens compared individual component of Sj26GST (P <
0.05). In addition, significant reductions of liver egg
counts were observed in SjGP-1 and SjGP-3 groups, but
not in SjGP-2 and SjGP-4 groups compared with control
group (Table 1). Notably, similar level of egg reduction
but much higher worm reduction was observed in SjGP-3
group compared with SjGP-1. Because of this, SjGP-3 was
selected for further investigation as a vaccine candidate
against shistosomiasis.
Immunogenicity of SjGP-3 formulations with various 
adjuvants
To investigate the effect of adjuvant on immunogenicity
of the chimeric protein, SjGP-3 was formulated in various
adjuvants, including complete Freund's adjuvant (CFA),
ISA 206, IMS 1312 and ISA 70M (SEPPIC, France). Mice
were immunized s.c. with 20 μg recombinant proteins. As
shown in Table 2, similar levels of total IgG were gener-
ated in CFA, ISA 206 and ISA 70M adjuvant groups while
ISM 1312 adjuvant produced much lower levels of anti-
body. Further analysis of the IgG isotypes and IgE revealed
that IgG1 was the predominant subclass in all of the adju-
vant groups. However, high levels of IgG2a were observed
in the protein groups formulated with ISA 70M that was
43, 18 and 5-fold higher than ISM 1312, ISA 206 and CFA
formulations respectively, while the titer of IgE in ISA
70M group was only1/10, 3/10 and 7/10 of that in CFA,
ISA 206 and IMS 1312 group respectively (Figure 2A). The
ratio of IgG2a/IgG1 in ISA70M group was the highest
compared to other groups (Figure 2B). These results were
repeatable in the second experiment. The data suggested
that distinctive types of immunity were induced by the
different adjuvants.
Effect of adjuvant on cytokine production
To determine the levels of Th1/Th2 cytokines in mice
immunized with SjGP-3 formulated with various adju-
vants, we isolated spleen cells of the immunized mice on
week 9, 12 and 15. The levels of IL-4 and IFN-γ were meas-
ured by ELISA in the supernatants of cultured splenocytes
Table 1: Antibody titers, worm and egg burdens, protective efficacy in mice vaccinated with schistosome chimeric proteins
Groupsa IgG Titersb Worm burden %Worm reduction Liver eggs (epg) % Egg reduction
Mean ± SE Mean ± SE c
SjGP-1 To SjGP-1 1,310,000 25.8 ± 1.3 27.7* 25,900 ± 2,124 27.7*
Pmy-F1 804,000
Sj26GST 112,000
SjGP-2 To SjGP-2 550,000 34.0 ± 1.6 4.2 32,100 ± 2,150 10.3
Pmy-F2 63,000
Sj26GST 19,000
SjGP-3 To SjGP-3 1,231,000 22.2 ± 1.6 37.5*,# 26,700 ± 2,011 25.4*
Pmy-F3 663,000
Sj26GST 142,000
SjGP-4 To SjGP-4 804,000 28.3 ± 1.9 20.7* 30,000 ± 3,291 16.2
Pmy-F4 136,000
Sj26GST 23,000
Sj26GST To Sj26GST 230,000 30.8 ± 1.4 13.7 28,100 ± 1,524 21.5*
Control To all above 500 35.7 ± 2.5 / 35,800 ± 3,178 /
a: The number of mice per group is from 9 to 10; b: "Pmy-F1" to "Pmy-F4" represents the four paramyosin fragments, respectively. Cut-off value was 
determined based on the pre-immunized geometric mean and three standard deviations. c: Number of liver eggs was calculated as egg numbers per 
gram of liver (epg). *: p < 0.05 when compared with PBS control group. #: p < 0.05 when compared with Sj26GST group. Each value was derived 
from the arithmetic means of individuals in the group.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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stimulated by SjGP-3 recombinant protein (30 μg/ml),
anti-CD3 (1 μg/ml) as positive control or medium as the
negative control. As shown in Figure 3, on week 9, signif-
icantly enhanced levels of both IL-4 and IFN-γ were
observed in all adjuvant groups, except in the ISA70M
group, where the IL-4 level declined significantly com-
pared with the other adjuvant groups (Figure 3A). IL-4 lev-
els were not significantly different between the SjGP-3/
70M and the control group, indicating that immune
response induced by SjGP-3/70M was towards a Th1-
dominant cytokine pattern. Interestingly, this cytokine
pattern generated by the SjGP-3 stimulation of the splen-
ocytes in vitro could be maintained throughout parasite
maturation (Figure 3B, week 12) and after onset of female
worm egg production (Figure 3C, week 15). In contrast to
results observed in ISA 70M group, production of IFN-γ
decreased in the SjGP-3/CFA, SjGP-3/206 and SjGP-3/
1312 groups on week 12 and 15 after infection, with no
significant difference in cytokine levels between immuni-
zation groups and control group, with the single excep-
tion of the CFA adjuvant group on week 12. However,
SjGP-3/CFA and SjGP-3/206 groups with minimal IFN-γ
production presented lasting high levels of IL-4, indicat-
ing a shift in dominant cytokine profile from the mixed
Th1/Th2 cytokine pattern to a Th2-dominant cytokine
SjGP-3-specific immunoglobulin subtypes (IgG1, IgG2a and IgE) Figure 2
SjGP-3-specific immunoglobulin subtypes (IgG1, IgG2a and IgE). Groups of mice were immunized with SjGP-3 formu-
lations. Serum was collected after three time immunization. IgG1, IgG2a and IgE titers were detected by ELISA in triplicate 
wells respectively and the IgG2a to IgG1 ratio was calculated. (A) Anti-SjGP-3 antibody titers. (B) IgG2a/IgG1 ratio. * p < 0.05 
when compared with other groups. This picture shows one experiment representative of two independent trials with similar 
results.
Table 2: Effects of immunization with the SjGP-3 formulated by various adjuvants on induction of IgG and protective efficacy against 
challenge in mice
Groups a IgG titers b Worm burdens
Mean ± SE
%Worm reduction Liver eggs (epg)
Mean ± SE c
% Egg reduction
Exp1 SjGP-3/CFA 1,890,000 19.8 ± 0.9 41.1* 20,900 ± 1,947 26.6*
SjGP-3/ISA206 1,290,000 23.4 ± 1.4 30.4* 21,200 ± 2,307 25.6*
SjGP-3/IMS1312 680,000 25.3 ± 1.2 24.7* 24,400 ± 2,604 14.4
SjGP-3/ISA70M 1,790,000 27.8 ± 1.2 17.3* 15,100 ± 1,578 47.0*,#
Control < 500 33.6 ± 1.0 / 28,500 ± 2,777 /
Exp2 SjGP-3/CFA 1,831,000 20.9 ± 1.2 38.2* 26,900 ± 2,557 29.6*
SjGP-3/ISA206 1,160,000 24.0 ± 1.6 29.0* 28,300 ± 1,808 25.9*
SjGP-3/IMS1312 783,000 24.7 ± 1.9 26.9* 31,500 ± 2,593 17.5
SjGP-3/ISA70M 1,841,000 26.0 ± 0.9 23.1* 19,000 ± 1,817 50.3*,#
Control < 500 33.8 ± 0.8 / 38,200 ± 3,428 /
a: The number of mice per group is from 8 to 10; b:Cut-off value was determined based on the pre-immunized geometric mean and three standard 
deviations. c: Number of liver eggs was calculated as egg numbers per gram of liver (epg). *: p < 0.05 when compared with PBS control group. #: p < 
0.05 when compared with other adjuvant groups. Each value was derived from the arithmetic means of individuals in the group.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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Analysis of cytokine production Figure 3
Analysis of cytokine production. Spleen cells were harvest from mice immunized with the SjGP-3 formulated by various 
adjuvants (three mice each group) on week 9 (before challenge), 12 (three weeks after cercarial challenge) and 15 (six weeks 
after cercarial challenge), and stimulated in vitro with anti-CD3, SjGP-3 protein or medium in duplicate wells respectively. The 
IL-4 and IFN-γ production in the culture supernatants of spleen cells was analyzed by ELISA in triplicate wells. Data correspond 
to the mean values ± standard deviation. (A) Week 9. (B) Week 12. (C) Week 15. * p < 0.05, ** p < 0.01 when compared 
with PBS control group.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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pattern after parasite maturation and onset of egg produc-
tion.
Effect of adjuvant on intracellular cytokine production by 
flowcytometry
To detect the percentage of CD3
+CD8- cells and CD3
+CD8+
cells in mice immunized with SjGP-3 formulations, we
isolated spleen cells on week 9. As shown in Figure 4,
compared with control group, the percentages of both
CD3
+CD8-IFN-γ+  cells, CD3
+CD8+IFN-γ+  cells and
CD3
+CD8-IL-4+  cells, CD3
+CD8+IL-4+  cells were signifi-
cantly increased in mice immunized three times with
SjGP-3/CFA, SjGP-3/206 or SjGP-3/1312, indicating
mixed Th1/Th2 immune responses were induced. Inter-
estingly, high percentages of CD3
+CD8-IFN-γ+ (14.26%)
and CD3
+CD8+IFN-γ+ (4.99%) cells were observed in the
SjGP-3/70M group, whereas there was no increase in
CD3
+CD8-IL-4+ or CD3
+CD8+IL-4+ cells compared with
that in control group, suggesting the immune response
was polarized to Th1 profile when mice immunized with
SjGP-3/70M. This was consistent with results for
cytokines in the supernatant of cultured splenocytes stim-
ulated by SjGP-3.
We also investigated percentages of CD3
+CD8- cells at var-
ious time points of post immunization in mice. On week
12, when the parasite was an adult but still not able to
produce eggs, the Th1/Th2 cytokine profiles changed (Fig-
ure 5A). The percentage of CD3
+CD8-IFN-γ+  cells
decreased to a level similar to CD3
+CD8-IL-4+ cells, with
the exception of the SjGP-3/70M group, where CD3
+CD8-
IFN-γ+ cells remained predominant. On week 15, after
onset of egg production and maturation, the Th1/Th2
cytokine profiles were further changed (Figure 5B). The
percentage of CD3
+CD8-IL-4+ cells significantly increased
by > 20% while the CD3
+CD8-IFN-γ+ cells decreased in all
groups, indicating development of an egg-specific polar-
ized Th2-type immune response. The FACS dot plots of
intracellular cytokine production of splenocytes after cer-
Detection of intracellular cytokine production of splenocyte in mice by flowcytometry after immunization Figure 4
Detection of intracellular cytokine production of splenocyte in mice by flowcytometry after immunization. 
Spleen cells of mice (three mice each group) immunized with the SjGP-3 formulated by various adjuvants were harvested after 
three times immunization (on week 9). The isolated splenocytes from individual mice were first stimulated with PMA, ionomy-
cin plus BFA. Splenocytes were stained extracellularly by PE-Cy5 labeled anti-CD3 and FITC labeled anti-CD8. After fixation 
and permeabilization, the spleen cells were divided into three tubes and stained intracellularly with PE conjugated Rat IgG1, 
anti-mouse IFN-γ antibody or anti-mouse IL-4 antibody, respectively. A FACScan flow cytometer with Cell Quest software was 
used for data acquisition and analysis. The percentage of PE positive cells in Rat IgG1 isotype control was less than 0.5% (data 
not shown).BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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carial challenge were shown as an on-line supplementary
figure (Additional file 1).
Correlation of Th1-dominant response with reduction of 
liver eggs
To investigate the effect of Th1 or Th2-dominant response
on protection against cercarial challenge, mice were
immunized with SjGP-3 formulated in various adjuvants.
As described above, the formulations with CFA, ISA 206
and ISM 1312 adjuvants induced a moderate mixed Th1/
Th2 response after three vaccinations. Subsequent chal-
lenge with schistosome cercariae produced higher per-
centages of worm reduction (41.1%, 30.4% and 24.7%,
respectively) but showed less efficacy of liver egg reduc-
tion (26.6%, 25.6% and 14.4%, respectively) in the first
experiment (Table 2, Exp 1). In contrast, the ISA70M adju-
vant formulation elicited a polarized Th1 response as
described above but generated little effect on worm bur-
dens (17.3% reduction) with a greater effect on egg depo-
sition in liver (47.0% egg reduction). All results were
repeatable in the second experiment (Table 2, Exp 2).
Additionally, we compared the number of liver eggs per
female produced in immunized mice with control group.
As shown in Figure 6, the number of liver eggs per female
was not significantly reduced in CFA, ISM 1312 and ISA
206 adjuvant groups. In contrast to these adjuvants, SjGP-
3 formulated with ISA 70M adjuvant induced a significant
reduction in the number of liver eggs per female at 37.2%
and 34.5% in the first and second experiments, respec-
tively.
Discussion
Poor protective efficacy is one of the main obstacles to
development of vaccines against schistosomes [24,25].
Although vaccination with UV-attenuated cercariae can
induce potent immunity against challenge-infection in
mice [26], the use of this approach is still controversial
[27]. Meanwhile, all the vaccine candidates used in large
animal experiments have been built on single protein
antigens, which do not provide consistently sufficient pro-
tection against S. japonicum [24]. Polyvalent subunit vac-
cines containing multiple protective domains or epitopes
from different antigens may be necessary for enhanced
immunogenicity and protective efficacy. Chimeric protein
vaccine constructs may be an approach towards this and
therefore, we have constructed four fusion proteins by
combining Sj26GST and paramyosin fragments. Immuni-
zation of mice with the chimeric proteins provided vari-
ous levels of protection against cercarial challenge. Of the
four chimeric proteins, SjGP-3 was shown to induce a
high level of protection in terms of reduced worm bur-
dens and lower liver egg counts. Moreover, immune sera
to this protein interacted with both native and recom-
binant Sj26GST and paramyosin. Importantly, this chi-
Detection of intracellular cytokine production of splenocytes in mice by flowcytometry after cercarial challenge Figure 5
Detection of intracellular cytokine production of splenocytes in mice by flowcytometry after cercarial chal-
lenge. Spleen cells of mice (three mice each group) immunized with the SjGP-3 formulated by various adjuvants were har-
vested on week 12 (three weeks after cercarial challenge) and 15 (six weeks after cercarial challenge). The isolated splenocytes 
from individual mice were first stimulated with PMA, ionomycin plus BFA. Splenocytes were stained extracellularly by PE-Cy5 
labeled anti-CD3 and FITC labeled anti-CD8. After fixation and permeabilization, the spleen cells were divided into three tubes 
and stained intracellularly with PE conjugated Rat IgG1, anti-mouse IFN-γ antibody or anti-mouse IL-4 antibody, respectively. A 
FACScan flow cytometer with Cell Quest software was used for data acquisition and analysis. (A) Week 12. (B) Week 15. * p 
< 0.05 when compared with PBS control group.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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meric protein provided greater protection in reduction of
worm burdens and egg counts than did its individual
component, Sj26GST. Therefore, SjGP-3 may be a suitable
candidate for further development as a vaccine against
schistosomiasis japonica.
Although it is generally agreed that a successful schisto-
somiasis vaccine will have the generation of an antigen-
specific CD4+ T cell response, it is still unclear which sub-
set of CD4+ T cells, Th1 or Th2, should be induced. Previ-
ous studies highlighted the important role of Th2-type
immune response in naturally acquired resistance to
infection [28-31]. However, this type of immune response
also plays a key role in granuloma formation and patho-
genesis of hepatic fibrosis in schistosomiasis [32]. There-
fore, the possibility that vaccination may induce a Th2
response and lead to more severe disease is of concern.
Other studies observed that high levels of protective
immunity were related with Th1-dependent mechanisms
in animals [33-35]. Recent publications showed that
manipulation of the immune response for sustained Th1
response or cercarial infection of IL-4 receptor deficient
mice resulted in reduced worm burdens or diminished
granuloma formation [36-38]. These results imply the
importance of the sustained Th1 response for anti-pathol-
ogy vaccine development. In addition, radiation attenu-
ated cercariae vaccine induced consistently high-level
protection against challenge infection. Single vaccination
of the irradiated cercariae elicited a Th1-dominant
response and the protective mechanism likely involved
cell-mediated immunity, with IFN-γ-activated macro-
phages and NO implicated [26,39,40].
Consistent with other findings [41,42], our results
showed the correlation of Th1-type polarization with
reduction of liver eggs and liver eggs per female. Several
parameters indicated that the immune response was
polarized to the Th1-type profile, and cellular and
humeral responses were enhanced in SjGP-3/70M group:
(1) IgG2a was elicited at 5- to 43-fold higher levels than
in the other adjuvant groups whereas IgE titers were lower
than that in all groups; (2) a Th1-dominant cytokine pat-
tern was detected in the supernatant of splenocyte stimu-
lated by the antigen; (3) the enhanced levels of IFN-γ were
lasting, whereas the IL-4 levels were similar to the control
group; and (4) consistent with the cytokine pattern, stain-
ing of splenocytes and flow cytometric analysis showed
that CD3+CD8-IFN-γ+ and CD3+CD8+IFN-γ+ cells in this
group were significantly increased, whereas CD3+CD8-IL-
4+ and CD3+CD8+IL-4+ cells were not increased compared
with control group. Since schistosome eggs are the princi-
pal cause of pathology in schistosomiasis, reduction in
liver egg may be a more meaningful endpoint than adult
worm burdens. Most researches on schistosomiasis vac-
cine focused on development of anti-worm vaccines.
However the reduction of worm burden induced by such
vaccines can't consistently supply 40% protection in chal-
lenge experiments, a level that the WHO believes neces-
sary for protection against schistosomiasis [5,25]. Thus,
development of an effective vaccine that could signifi-
cantly reduce female egg production so that tissue egg bur-
dens are lowered to a level where little morbidity and
mortality occurs and parasite transmission is limited. The
immune mechanism underlying this protection is
unclear. In this study, we observed cercarial challenge of
mice with the polarized Th1-type response resulted in sig-
nificantly reduced the number of liver eggs per female
(34.5–37.2%), whereas the number of liver eggs per
female was not reduced in the other groups. This might
suggest that anti-fecundity protective immunity was
induced by deviating immune response towards Th1
polarization. However, attenuated cercariae did not
induce such anti-fecundity effect in immunized mice even
though this immunization stimulated strong Th1
response [42]. Thus, it is necessary to analyze whether
Effect of different adjuvant on liver egg numbers per female  worm Figure 6
Effect of different adjuvant on liver egg numbers per 
female worm. Liver egg numbers per female worm was 
measured by total number of liver eggs/total number of 
paired female worm of individual mouse. The reduction rate 
of liver eggs per female worm was calculated according to 
the following formula: (1- mean number of liver eggs per 
female worm in immunized mice/mean number of liver eggs 
per female worm in control mice) × 100. There was a signifi-
cant reduction of the number of liver eggs per female in ISA 
70M groups at 34.5–37.2%, while the number of liver eggs 
per female was not significantly reduced in CFA, ISM 1312 
and ISA 206 adjuvant groups (Exp 1: 0.6%, 1.9% and -3.2%; 
Exp 2: -4.1%, -3.4% and -12.5%, respectively). The number of 
mice per group is from 8 to 10. * p < 0.05 when compared 
with PBS control group. This picture shows one experiment 
representative of two independent trials with similar results.BMC Infectious Diseases 2009, 9:54 http://www.biomedcentral.com/1471-2334/9/54
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SjGP-3/70M induced anti-fecundity immunity is under-
mined in IFN-γ-/- mice.
SjGP-3 formulated in various adjuvants induced different
types of immune responses. However, the SjGP-3-induced
immune response patterns were significantly modulated
by parasite antigens. The Th1-dominant pattern in the
SjGP-3/70M group was modulated after cercarial infec-
tion, revealing the CD3+CD8-IL-4+ cells expand dramati-
cally after parasite maturation. Moreover, the immune
response was further polarized to a Th2-type profile after
the onset of egg production by the parasites and their mat-
uration. This data suggested that the SjGP-3-induced
polarized Th1 response failed to prevent the shift from
Th1 to Th2 transition normally occurring in infected mice
after the onset of female worm egg production. Cytokine
production in culture supernatants of spleen cells stimu-
lated by SjGP-3 did not appear to change to the intracellu-
lar cytokine patterns after cercarial challenge, but this may
be due to the inability of the detection methodology to
detect cytokines secreted by anything other than SjGP-3-
specific lymphocytes. We noticed the discrepancy of
cytokine pattern changes between SjGP-3 stimulation and
anti-CD3 stimulation. When the cells were stimulated by
anti-CD3 at an antigen non-specific fashion for 72 hrs, all
subsets of Th cells including Th0, Th1 and Th2 would be
activated and corresponding cytokines would be pro-
duced. Therefore, when the polarized Th1 cells in the
SjGP-3/70M group were activated with anti-CD3, the Th0
cells mixed in them will also be activated by anti-CD3 to
generate IL-4. This IL-4 will create difficulties in the deter-
mination of Th1 phenotype. On the other hand, the large
amount of IFN-γ generated by Th0 cells from control
group made us hard to see an increased IFN-γ production
in SjGP-3/70M group as that found in antigen specific
stimulation fashion. These two factors collectively made
us fail to demonstrate Th1 development in anti-CD3 stim-
ulation. Concerning the intracellular cytokine staining
results of SjGP/70M group shown in Figure 4 and Figure
5A which actually showed Th1 phenotype even with anti-
gen non-specific stimuli PMA and ionomycin, our expla-
nation is that the activation time only lasted for 6 hrs in
vitro. This short time non-specific stimulation will only
reactivate those Th cells which were activated and polar-
ized in vivo by SjGP-3/70M. For this reason, Th1 pheno-
type demonstrated by FACS data was in consistent with
the Th1 phenotype demonstrated by measurement of
cytokine production stimulated by antigen in vitro.
S. japonicum is a zoonotic parasite. Domestic animals,
especially water buffalo, are the major reservoirs for S.
japonicum infection in China and responsible for 75% of
human transmission [43]. Mathematical modeling of S.
japonicum transmission dynamics in China revealed that
an anti-fecundity bovine vaccine to a level at 75% efficacy
ensured the reduction of parasite in human population
[44]. Although a vaccine specific for use in humans may
be developed in the future, development of a veterinary
vaccine may be a practical interim strategy. Few veterinary
adjuvants have been identified for schistosomiasis vaccine
development; therefore, selection of appropriate adju-
vants is an important first step in this process. Here, we
compared the effect of four adjuvants (CFA, ISA 206, IMS
1312 and ISA 70M) combined with SjGP-3 in mice chal-
lenge experiments. ISA 206, IMS 1312 and ISA 70M are
known as veterinary adjuvants and represent three differ-
ent kinds of emulsions, the water-in-oil (ISA70M), the
water-in-oil-in-water (ISA 206) and the nanoparticles of
IMS 1312 [45,46]. We found the use of adjuvant exhibited
a profound improvement on the protection efficacy of
SjGP-3 in S. japonicum challenge in mice. Of the novel
adjuvants used in this study, ISA70M comprises a high
grade injectable mineral oil and an extremely refined
emulsifier obtained from mannitol and purified oleic acid
of vegetable origin. This adjuvant is a modified version of
a successfully used animal adjuvant ISA 70 [47]. Interest-
ingly, the SjGP-3 antigen when formulated with this adju-
vant induced enhancement in both humoral and cell-
mediated immune response, by developing a polarized
Th1 response resulting in significant reduction of liver
eggs.
Conclusion
In conclusion, construction of polyvalent subunit vaccine
was capable to enhance immunogenicity and protection
efficacy against schistosomiasis japonica. There was corre-
lation of the polarized Th1 response with reduction of
liver egg burdens, indicating the immune deviation strat-
egy for schistosomiasis japonica vaccine development.
These data support further investigation of the SjGP-3 for-
mulation with ISA 70M as a potential vaccine for animal
use.
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